Clinical Trials (Phase I)
Filter News
Found 11,408 articles
-
RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer
10/20/2017
The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication.
-
Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin's Lymphoma
10/20/2017
G100 is a product candidate from Immune Design's GLAAS discovery platform.
-
Creative Medical Technology Announces Commercialization of Patented Stem Cell Procedure for Erectile Dysfunction
10/20/2017
Creative Medical Technology Holdings announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem procedure.
-
CStone Pharma Announces Dosing the First Patient of CS1001: China's First Fully Human, Full-length Anti-PD-L1 Monoclonal Antibody
10/20/2017
CStone Pharma, Ltd. announced today that the first human clinical trial of CS1001, China's first fully human and full-length anti-PD-L1 monoclonal antibody, had successfully dosed the first patient in Beijing Cancer Hospital.
-
Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia
10/20/2017
Esanex, Inc., a clinical stage company developing Heat Shock Protein inhibitors for the treatment of cancer, today announced the first patient has been dosed in an open-label study of SNX-5422 added to ibrutinib.
-
The company plans to expeditiously advance AMT-061 instead of AMT-060.
-
FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome
10/19/2017
Pluristem’s ARS program is developed and funded by the U.S. National Institutes of Health and the U.S. Department of Defense, and is in preparation for a pivotal study.
-
Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
10/19/2017
Enrollment to begin in Australia; U.S. sites expected to open in early 2018.
-
Biscayne Neurotherapeutics Reports Successful Phase Ib Clinical Trial Results For Its Novel Antiepileptic Agent
10/19/2017
Biscayne Neurotherapeutics announced results from a Phase 1b trial of its novel antiepileptic compound, BIS-001ER.
-
Calithera Announces First Patient Treated in Phase I Cohort of INCB01158 Dosed in Combination With Keytruda
10/19/2017
The Phase 1 trial is designed to evaluate the safety and recommended Phase 2 dose of INCB01158 as a monotherapy, and in combination with immune checkpoint therapy.
-
ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial With TXL
10/19/2017
-
Synspira Announces First Patient Dosed In Phase 1a Study Of SNSP113 In Cystic Fibrosis
10/19/2017
Synspir announced initiation of a Phase 1a first-in-human, multi-center study of SNSP113, its lead drug candidate, in development for use in pulmonary complications of cystic fibrosis (CF).
-
Dynavax Initiates Clinical Trial In Non-Small Cell Lung Cancer With A Novel Inhaled TLR9 Agonist In Combination With Anti-PD-1 Therapy
10/19/2017
Dynavax Technologies Corporation announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC).
-
PharmaMar Release: Final Data on Phase I/II in Small-cell Lung Cancer with Zepsyre Presented at the IASCLC 18th World Conference on Lung Cancer in Japan
10/18/2017
PharmaMar has presented updated data from Zepsyre Phase I/II trials in relapse small cell lung cancer in an oral presentation at the International Association for the Study of Lung Cancer (IASLC), at 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan.
-
XBiotech Announces First Patient in Study Evaluating MABp1 in Combination With Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
10/18/2017
The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator.
-
Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset
10/18/2017
The full dataset is being reserved for a future publication.
-
BioLineRx Announces Initiation of Phase Ib/2 Trial for BL-80040 in Gastric Cancer Under Immunotherapy Collaboration
10/18/2017
BioLineRx announced today that Genentech has commenced a Phase 1b/2 study for the treatment of gastric cancer with BL-8040 in combination with atezolizumab, Genentech's anti-PDL1 cancer immunotherapy agent.
-
Mutabilis Joins The European ENABLE Consortium To Fight Antibiotic Resistance
10/18/2017
Mutabilis announces its selection by the European ENABLE project (European Gram-negative Antibacterial Engine), which aims to improve the development of antibiotics against infections caused by multiresistant Gram-negative bacteria.
-
M3 Biotechnology Launches Clinical Trials For Alzheimer’s Disease Drug Focused On Restoring Lost Connections In The Brain
10/18/2017
A six-year-old biotech company at the leading edge of regenerative medicine is bringing a therapy for Alzheimer’s to Phase I clinical trials that is expected to slow or stop disease progression as indicated by pre-clinical studies, announced M3 CEO Leen Kawas.
-
Voyager Therapeutics Announces New Data Presentations at the Congress of the European Society of ...
10/17/2017
The data includes an oral presentation related to recent results from Voyager's ongoing Phase 1b trial of VY-AADC01 in advanced Parkinson's disease.